ALK and lung carcinoma: Further, a clinical study detecting ALK fusions in lung cancer reported a positive predictive value between sequencing and FISH as 68% (19/28) among diagnostic characterized patients, and only 46% (6/13) when reduced to those patients with clinical outcomes (11/13 were sequencing positive and partial responders to crizotinib) [20].